115 related articles for article (PubMed ID: 19744571)
1. Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML).
Klyuchnikov E; Kröger N; Brummendorf TH; Wiedemann B; Zander AR; Bacher U
Biol Blood Marrow Transplant; 2010 Mar; 16(3):301-10. PubMed ID: 19744571
[TBL] [Abstract][Full Text] [Related]
2. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
3. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
Wright MP; Shepherd JD; Barnett MJ; Nantel SH; Sutherland HJ; Toze CL; Hogge DE; Nevill TJ; Song KW; Abou Mourad YR; Narayanan S; Power MM; Smith CA; Forrest DL
Biol Blood Marrow Transplant; 2010 May; 16(5):639-46. PubMed ID: 20005967
[TBL] [Abstract][Full Text] [Related]
4. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
[TBL] [Abstract][Full Text] [Related]
5. Advanced CML: therapeutic options for patients in accelerated and blast phases.
Shah NP
J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S31-S36. PubMed ID: 18397679
[TBL] [Abstract][Full Text] [Related]
6. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
7. Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors--a synthesis of clinical and laboratory data.
Irvine DA; Heaney NB; Holyoake TL
Blood Rev; 2010 Jan; 24(1):1-9. PubMed ID: 20005615
[TBL] [Abstract][Full Text] [Related]
8. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
9. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
10. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
11. Current and emerging treatment options in chronic myeloid leukemia.
Jabbour E; Cortes JE; Giles FJ; O'Brien S; Kantarjian HM
Cancer; 2007 Jun; 109(11):2171-81. PubMed ID: 17431887
[TBL] [Abstract][Full Text] [Related]
12. Controversies in the treatment of CML in children and adolescents: TKIs versus BMT?
Suttorp M; Yaniv I; Schultz KR
Biol Blood Marrow Transplant; 2011 Jan; 17(1 Suppl):S115-22. PubMed ID: 21195300
[TBL] [Abstract][Full Text] [Related]
13. Treatment strategies for CML.
Goldman JM
Best Pract Res Clin Haematol; 2009 Sep; 22(3):303-13. PubMed ID: 19959082
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?
Ruiz-Argüelles GJ; Tarin-Arzaga LC; Gonzalez-Carrillo ML; Gutierrez-Riveroll KI; Rangel-Malo R; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Gómez-Almaguer D; Giralt S
Bone Marrow Transplant; 2008 Jul; 42(1):23-8. PubMed ID: 18612313
[TBL] [Abstract][Full Text] [Related]
16. Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.
Gafter-Gvili A; Ram R; Gafter U; Shpilberg O; Raanani P
Leuk Res; 2010 Jan; 34(1):123-7. PubMed ID: 19640584
[TBL] [Abstract][Full Text] [Related]
17. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?
Maziarz RT
Curr Opin Hematol; 2008 Mar; 15(2):127-33. PubMed ID: 18300759
[TBL] [Abstract][Full Text] [Related]
18. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
19. Current role of stem cell transplantation in chronic myeloid leukaemia.
Gratwohl A; Heim D
Best Pract Res Clin Haematol; 2009 Sep; 22(3):431-43. PubMed ID: 19959092
[TBL] [Abstract][Full Text] [Related]
20. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications.
Kantarjian H; O'Brien S; Cortes J; Giles F; Thomas D; Kornblau S; Shan J; Beth Rios M; Keating M; Freireich E; Talpaz M
Cancer; 2003 Jul; 98(1):81-5. PubMed ID: 12833459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
